Skip to main content

Market Overview

Recap: Salarius Pharmaceuticals Q4 Earnings


Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) higher in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 77.27% over the past year to ($0.10), which beat the estimate of ($0.11).

Revenue of $1,479,000 higher by 42.35% year over year, which missed the estimate of $1,480,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Mar 18, 2021

Time: 04:30 PM

ET Webcast URL:


52-week high: $3.50

52-week low: $0.56

Price action over last quarter: Up 112.16%

Company Profile

Salarius Pharmaceuticals Inc is a biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. Its lead compound Seclidemstat is in clinical development for treating Ewing sarcoma.


Related Articles (SLRX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings